BOD (Mr. Klump and his advisors) vetted Vyera and Mr. Averill Powers and were impressed. They share our vision that leronlimab can compete with Gilead's of the world and they are hungry to prove themselves.

Vyera as commercialization will decide price and CYDY has a $45,000 floor. Launch at $60,000.

https://www.proactiveinvestors.com/companies/...09476.html